Global Protein Therapeutics Market (2021 to 2026)

DUBLIN, Oct. 18, 2021 /PRNewswire/ — The “Protein Therapeutics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026” report has been added to ResearchAndMarkets.com’s offering.

The global protein therapeutics market exhibited moderate growth during 2015-2020. Looking forward, the market is expected to grow at a CAGR of around 6% during 2021-2026. Keeping in mind the uncertainties of COVID-19, the analyst is continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end-use industries. These insights are included in the report as a major market contributor.

Protein therapeutics refers to artificially synthesized protein-based medicines. They are fast-acting, potent medicines that deliver small protein molecules to the body in a specific amount. They usually consist of recombinant forms of naturally occurring proteins, such as monoclonal antibodies, insulin, fusion proteins, erythropoietin, interferon, human growth hormones (HGH) and follicle-stimulating hormones. They aid in treating chronic medical ailments, such as cancer, diabetes, neurodegenerative disorders and immunological, hematological, hormonal and genetic disorders. Various combination therapy drugs are also used with protein therapeutics that can be inhaled, injected or orally administered.

The increasing prevalence of chronic medical ailments is one of the key factors driving the growth of the protein therapeutics market. In line with this, the rising awareness among the masses regarding the benefits of protein therapeutics, such as minimal risks of side effects and high efficiency, are contributing to the market growth. Monoclonal antibodies are being widely researched and used for the treatment of various viral and bacterial diseases and pharmaceutical companies are using protein therapeutics for drug discovery and development. The sudden outbreak of the coronavirus disease (COVID-19) is further providing growth opportunities to market players. For instance, Molecular Partners AG, a Switzerland-based clinical stage biotechnology company, is developing a new class of protein therapeutics, called DARPin, to inhibit the proliferation of the virus.

The development of novel recombinant proteins, peptides, antibody-based drugs and plasma proteins is acting as other-growth inducing factors. These protein therapeutics are extensively used in replacement therapies to treat genetic and autoimmune disorders, such as dysfibrinogenemia, afibrinogenemia, and hypofibrinogenemia. Other factors, including extensive research and development (R&D) activities in the field of protein engineering, along with significant improvements in the healthcare infrastructure, are expected to drive the market further.

Story continues

Competitive Landscape

The report has also analysed the competitive landscape of the market with some of the key players being Amgen Inc., Abbott Laboratories, Abbvie Inc.,…